Join        Login             Stock Quote

Analyst View, Impact of Global Events - Research Report on Johnson & Johnson and Endo Pharmaceuticals

Thursday, October 20, 2011 9:00 AM


HONG KONG -- (Marketwire) -- 10/20/11 -- Today, www.WorldStreetFundamentals.com released its industry report highlighting Johnson & Johnson (NYSE: JNJ) and Endo Pharmaceuticals (NASDAQ: ENDP). Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php?id=JNJ+ENDP.

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

World Street Fundamentals has highlighted Johnson & Johnson for its current position within the healthcare industry. Johnson & Johnson is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the health care field. It has more than 250 operating companies conducting business worldwide. The entire report on Johnson & Johnson (NYSE: JNJ) is available here: www.WorldStreetFundamentals.com/Report.php?id=JNJ.

World Street has featured Endo Pharmaceuticals for its development within the healthcare industry. Endo Pharmaceuticals Holdings Inc. (Endo) is a specialty healthcare solutions company focused on branded products and generics, and devices and services. The Company has a portfolio of branded pharmaceuticals, which includes brand names, such as Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar, and Supprelin LA. The entire report on Endo Pharmaceuticals (NASDAQ: ENDP) is available here: www.WorldStreetFundamentals.com/Report.php?id=ENDP.

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets.


Adam Redford
Email Contact

(Source: Market Wire )
(Source: Quotemedia)


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.